Connect Biopharma Holdings Limited Current Financial Assets At Fair Value Through Profit Or Loss
Connect Biopharma Holdings Limited (CNTB) had Current Financial Assets At Fair Value Through Profit Or Loss of CNY 13.07 million as of 2020-12-31, per its 20-F filed 2022-03-31.
Discontinued › Notes
ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss · last filed 2022-03-31
- 2020-12-31: Current Financial Assets At Fair Value Through Profit Or Loss 13.07M CNY.
| Period end | Current Financial Assets At Fair Value Through Profit Or Loss |
|---|---|
| 2020-12-31 | 13.07M CNY 20-F · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |